PROSNACO: Evaluation of the Autonomic Nervous System in Patients Undergoing Esophagectomy for Cancer

Sponsor
Centre Hospitalier Universitaire de Saint Etienne (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04835987
Collaborator
(none)
15
1
21
0.7

Study Details

Study Description

Brief Summary

Esophageal surgery is a complex surgery, with high post-operative morbidity and mortality. The incidence of complications associated with esophagectomy varies from 17% to 74%, in the literature. A section of vagus nerves is conventionally performed during esophagectomy for cancer, because of oncological margins. The vagus nerve is responsible for the parasympathetic innervation at the gastrointestinal level, but also at the cardiac and pulmonary level. The post-operative morbidity of these procedures could be linked in part to the bilateral section of the vagus nerves, because of their impact on the autonomous regulation of this vital functions. The main objective of the study is to find a modification of the sympathomimetic balance pre and post operatively, in patients undergoing esophagectomy.

Condition or Disease Intervention/Treatment Phase
  • Diagnostic Test: Holter ECG
  • Behavioral: Questionary
  • Diagnostic Test: Pupillometry

Detailed Description

The sympathomimetic balance was measured using a Holter-ECG heart rate monitor. The parameters collected were used to calculate the variability of the heart rate, the high frequencies (HF, reflection of the parasympathetic system), the low frequencies (LF, reflection of the sympathetic system and the parasympathetic system) and the ratio // LF / HF (reflection of the sympathetic activity) thanks to Fourier analysis and the use of HRVanalysis software.

The measurements were taken at night, to overcome the great sympathomimetic variabilities due to external stimulations during the day: one night 3 month before surgery/before the first chemotherapy, one night between 2 and 4 weeks before hospitalization (remotely of possible chemotherapy), the night before the intervention (context of hospitalization and preoperative stress), one night between D7 and D10 (context of hospitalization, and distance from anesthetic drugs), one night at home between 4 and 8 weeks post-operative, and one night at home at 3 months post-operative.

The measurements were therefore not carried out the first nights following the intervention to overcome the anesthetic drugs that affect the balance of the autonomic nervous system.

A baroreflex measurement was carried out at the patient's entrance, the day before the intervention, during hospitalization, and the day of discharge. This measure was renewed at 3 months.

A measurement of patient activity was carried out preoperatively by wearing an actimeter watch for 1 week then renewed at 3 months.

A Respiratory Functional Exploration associated with a stress test with calculation of the VO2max is systematically carried out before the esophageal surgery. A Respiratory Functional Exploration was renewed 4 to 8 weeks after the intervention, and then at 3 months. the 6-minute walk test was performed at the same time.

Study Design

Study Type:
Observational
Anticipated Enrollment :
15 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Prospective Monocentric Evaluation of the Autonomic Nervous System in Patients Undergoing Esophagectomy for Cancer
Anticipated Study Start Date :
Dec 1, 2021
Anticipated Primary Completion Date :
Mar 1, 2023
Anticipated Study Completion Date :
Sep 1, 2023

Outcome Measures

Primary Outcome Measures

  1. Analysis of Standard deviation of all NN (SDNN) (ms) [before surgery]

    Analysis of Standard deviation of all NN (SDNN) intervals, over the entire registration period, provides information on global variability. Measured by Holter results. Day 0 = surgery

  2. Analysis of Standard deviation of all NN (SDNN) (ms) [day 7 to day 90]

    Analysis of Standard deviation of all NN (SDNN) intervals, over the entire registration period, provides information on global variability. Measured by Holter results. Day 0 = surgery

Secondary Outcome Measures

  1. HF activity [before surgery : Day -82, Day -30, Day -1]

    Day 0 = surgery measured with the Holter Electrocardiogram

  2. LF activity [before surgery : Day -82, Day -30, Day -1]

    Day 0 = surgery measured with the Holter Electrocardiogram

  3. LF/HF ratio [before surgery : Day -82, Day -30, Day -1]

    Day 0 = surgery measured with the Holter Electrocardiogram

  4. HF activity [after surgery : day 7, day 60, day 90]

    Day 0 = surgery measured with the Holter Electrocardiogram

  5. LF activity [after surgery : day 7, day 60, day 90]

    Day 0 = surgery measured with the Holter Electrocardiogram

  6. LF/HF ratio [after surgery : day 7, day 60, day 90]

    Day 0 = surgery measured with the Holter Electrocardiogram

  7. change in baroreflex [Day -1, Day 7, day discharge, day 90]

    baroreflex sensitivity : ms/mmHg Day 0 = surgery

  8. modify the respiratory functional exploration [Day -30, Day 30, Day 60]

    Peak expiratory volume per second : L Day 0 = surgery

  9. intraoperative pupillometry [during surgery]

    pupillary diameter : mm

  10. physical capacity [Day-30, Day 30, Day 90]

    walking distance in 6 minutes Day 0 = surgery

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Esophagectomy for cancer

  • written and oral agreement

Exclusion Criteria:
  • pregnant women,

  • patients with permanent atrial fibrillation,

  • patients with pace-maker

  • Patients under guardianship/curatorship

Contacts and Locations

Locations

Site City State Country Postal Code
1 Centre Hospitalier Universitaire de Saint-Etienne Saint-Étienne France 42055

Sponsors and Collaborators

  • Centre Hospitalier Universitaire de Saint Etienne

Investigators

  • Principal Investigator: EVE HUART, MD, CHU ST ETIENNE

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Centre Hospitalier Universitaire de Saint Etienne
ClinicalTrials.gov Identifier:
NCT04835987
Other Study ID Numbers:
  • 20CH250
  • 2020-A03326-33
First Posted:
Apr 8, 2021
Last Update Posted:
Dec 2, 2021
Last Verified:
Dec 1, 2021
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Centre Hospitalier Universitaire de Saint Etienne

Study Results

No Results Posted as of Dec 2, 2021